Improvement in Noninvasive Markers of Fibrosis (LSM, FIB-4, and APRI) Is Seen Over 96 Weeks of Bulevirtide Monotherapy in Chronic Hepatitis Delta Regardless of Virologic Response

Conference Reports for NATAP

AASLD
The Liver Meeting
November Fri, Nov 10, 2023 - Mon, Nov 14, 2023


Improvement in Noninvasive Markers of Fibrosis (LSM, FIB-4, and APRI) Is Seen Over 96 Weeks of Bulevirtide Monotherapy in Chronic Hepatitis Delta Regardless of Virologic Response

	AASLD Nov 10-14 https://www.aasld.org/the-liver-meeting